A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse (REV)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01111903|
Recruitment Status : Completed
First Posted : April 28, 2010
Last Update Posted : March 17, 2016
|Condition or disease||Intervention/treatment||Phase|
|Ovarian Cancer Recurrent||Drug: Lenalidomide||Phase 1 Phase 2|
Stage A: To determine efficacy of lenalidomide as single agent in patients with recurrent ovarian cancer in second or third line.
Stage B: To determine the Maximum Tolerated Dose (MTD) of lenalidomide in combination with chemotherapy consisting of carboplatin and pegylated liposomal doxorubicin.
Substudy: To investigate the impact of the lenalidomide on patients' immune system affected by cancer and to look for an immunizing marker which could be predictive of the activity of the lenalidomide in the solid tumors.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||67 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Two Stage Trial of lénalidomide (Revlimid®) : a Phase II Study of lénalidomide as Single Agent in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse: Followed by a Phase I of lénalidomide in Combination With Carboplatin and Liposomal Pegylated Doxorubicin.|
|Study Start Date :||May 2009|
|Actual Primary Completion Date :||December 2014|
|Actual Study Completion Date :||December 2014|
Phase II: lenalidomide 20 mg/day in continuous regimen. Phase I: lenalidomide 25 mg/day 21 days/28 + carboplatin AUC 5 + caelyx 30 mg/m2
Phase II: 20 mg/day in continuous regimen Phase I: 25 mg/day 21 days/28 with carboplatine AUC 5 + caelyx 30mg/m2
- Efficacy of lenalidomide as single agent, then DMT of lenalidomise with carboplatin and pegylated liposomal doxorubicin [ Time Frame: Rate of Tumor Response + Stable Disease (at 4 months) / DMT ]
STAGE A: To determine efficacy of lenalidomide as single agent in patients with recurrent ovarian cancer in second or third line.
STAGE B: To determine the Maximum Tolerated Dose (MTD) of lenalidomide in combination with chemotherapy consisting of carboplatin and pegylated liposomal doxorubicin.
- Safety profile of lenalidomide as single agent, then in combination [ Time Frame: Response rate, Stable Disease rate at 4 months / MDT ]
- To determine the safety profile of lenalidomide (type, frequency, severity, and relationship of adverse events to study treatment).
- To assess time to progression (TTP).
- To evaluate the safety profile of the combination therapy.
- To determine the response rate.
- To assess time to progression.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01111903
|Paris, France, 75020|
|Principal Investigator:||Frédéric SELLE, MD||Hôpital Tenon|